healthcare sector in india monthly update april 2013
TRANSCRIPT
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 1/15
Healthcare Sector in India
Monthly Update
April 2013
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 2/15
Healthcare – Monthly Update
Top Story
NRA
accredited
for
meeting
WHO
standards
Indian vaccine industry has reached an all time high with the World Health Organization
(WHO) declaring India's vaccine regulatory system meeting international standards. The
comprehensive review was conducted by an expert WHO team from 8 countries in Dec 2012.
The National Regulatory Authority of India (NRA) and its affiliated institutions have been
adjudged for fulfillment of WHO efficacy indicators for a functional vaccine regulatory
system.
The latest accreditation will pave the way for easy export of vaccines produced in the
country since the conformity to WHO standards guarantees Indian vaccine production lines
to be efficacious and safe and easily trusted.
News Update
General
Glivec faces patent plea dismissal
The Supreme Court declined Novartis AG's petition for patent protection of its cancer drug
Glivec although it has been patented in nearly 40 countries including the United States,
Russia and China. The Supreme Court dismissed the plea on the grounds of exorbitant price
and it not being a new medicine but an amended version of a known compound.
The legal blow has affected major pharma MNCs who target Indian market for driving sales.
The ruling has on the other hand been a boost for healthcare activists who have been
constantly demanding from the government to make medicines cheaper since patented
drugs constitute below 10% of total drug sales in India.
MSD Pharma files patent infringement litigation against Glenmark The USA based pharmaceutical company MSD Pharma has moved to the Delhi High Court to
bar Mumbai‐based Glenmark from selling generic versions of its anti diabetic drugs.
Glenmark Pharma launched generic versions of MSD Pharma’s anti diabetic drugs Januvia
and Janumet, under the names Zita and Zita Met last week. The generic version is beingmarketed at 20% rebated price to that of the innovator’s version that costs approximately
INR 40 per tablet.
Januvia and Janumet are patent protected for 20 years that was launched in 2008. Indian
jurisdiction of allowing launch of cheaper generic versions of existing patent protected drugs
is resulting in stiff competition between innovators and generic drug manufacturers.
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 3/15
Healthcare – Monthly Update
Shasun Pharmaceuticals pacts with Debiopharm S.A.
Chennai based Shasun Pharmaceuticals has entered a licensing agreement with Switzerland‐
based Debiopharm S.A. for manufacture and promotion of Huperzine‐A. The drug is a
treatment of Alzheimer's disease. As per the agreement Shasun would be able to use theDebiopharm technology for manufacturing synthetic Huperzine‐A.
Huperzine‐A is proven to be a potent and reversible acetylcholinesterase inhibitor which can
remarkably improve memory deficit and cognitive performance in patients with Alzheimer's
disease.
News Update
Regulatory
Panel formed to plug irregularities in drug marketing A 4‐member committee has been formed to look into reviewing of practices and procedures
adopted by the drug controller and fix responsibilities. The committee will be led by former
Director of Institute of Medical Sciences, Banaras Hindu University, Varanasi, and T.M
Mahapatra along with former scientist Satyawan Singh of Central Drug Research Institute,
Lucknow, former Kerala Drug Controller Venkat Krishnan and a representative of the Chief
Vigilance Officer of Union Ministry of Health and Family Welfare as its members.
The panel will keep an eye on the Central Drugs Standard Control Organisation (CDSCO)
strict adherence to scientific requirements and regulatory compliance in granting marketingapproval and clinical trials on new drugs including fixed dose combinations. The committee
is also seeking the active involvement of Drug Controller General of India (DCGI) to enquire
into unlawful drug practices in the country, thereby helping in controlling illegal approval of
drugs in India.
KMSCL sells life saving drugs at subsidized rate
The Kerala government has initiated a remarkable strategy of controlling price of life saving
drugs. A government‐owned enterprise The Kerala Medical Services Corporation Ltd.
(KMSCL) is offering drugs at a substantially low price, even to the extent of one sixth the
price at which such drugs are available in retail stores.
KMSCL has taken upon this initiative by procuring medicines in bulk at a heavily discounted
price from drug manufacturers directly. The medicines thus procured are sold through a
chain of stores called Karunya that are located at five medical colleges in the state.
70 additional hospitals to get empanelled
The Indian Health Ministry is in the process of expanding healthcare service options in the
NCR for the central government employees. The Health Ministry is currently reviewing the
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 4/15
Healthcare – Monthly Update
list of private hospitals, dental clinics and diagnostic facilities empanelled with the
government that would facilitate addition of at least 70 more private hospitals, eye care
centers and diagnostic facilities.
Around 10 new super and multispecialty hospitals, 10 mid segment general purpose
hospitals, 33 eye care centers, 10 dental clinics and 10 laboratories are in the process of
being empanelled. BL Kapoor Super Specialty Hospital, Max Hospitals at Patparganj and
Shalimar Bagh, Batra Hospital near Okhla, Rockland Hospital in South Delhi and Saroj
Hospital in Rohini are some of the hospitals to be included in the list of empanelled hospitals
among others. This would raise the total number of empanelled hospitals from current 130
to 200.
Pharmexcil to set up pharma storage warehouses abroad
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is in plans to set up
warehouse facilities in Latin America, Africa and Europe under the 'Brand India Pharma'campaign. The initiative is in view to encourage export business of small and medium Indian
pharma companies.
The warehouses will help the small and medium exporting pharma companies to stock their
products in desired conditions and supply as according to requirement. The Nigerian facility
is expected to be ready by Jun 2013. Pharmexcil has also announced that the 1st overseas
warehouse will give 75%, 50% and 33% subsidies for 3 years, respectively, to the user‐
companies.
Rajasthan Government drives Indian healthcare industry by free distribution of
Imatinib
Rajasthan Medical Services Corporation (RMSC) will be distributing generic version of
Novartis AG's Glivec (Imatinib) tablet for free from special counters at government hospitals.
This comes as part of Rajasthan Governments’ free medicine distribution scheme that was
launched in Oct 2010.
The blood cancer (chronic myeloid leukemia) medication, Glivec is currently sold at INR
0.12mn for a pack of 30 tablets. Blood cancer patients have to take one tablet daily, and in
order to bring relief to such patients, the state health department has decided to distribute
generic Imatinib tablets for free. The government is making an addition of 14 new anti‐
cancer drugs to be distributed free of cost totaling the cancer drugs provided for free to 39.
The pharma companies, who have shown interest in the project include Cipla, Glenmark,Naprod Life Sciences, United Biotech India and West Coast Pharmaceuticals.
Indian pharmaceutical sector soon to realize drug pricing policy
In a move to bring generic medicines under price control, the government has issued letters
to 4,000 Indian pharmaceutical industry manufacturers across the country to submit
relevant data. However, till now it has received responses from around 400 drug
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 5/15
Healthcare – Monthly Update
manufacturers from the states of Maharashtra, Himachal Pradesh, Rajasthan, Gujarat and
Andhra Pradesh.
In accordance to the new pricing policy, the National Pharmaceutical Pricing Authority(NPPA) has asked pharmaceutical companies to submit complete data related to essential
medicines in order to fix their prices. The NPAA has also gone further by asking pharma
associations to ask their respective members to submit relevant data so that the 348
"essential" drugs pricing under National List of Essential Medicines (NLEM) could completed
in time.
News Update
Expansion
Plans
Dr Reddy’s launches Reclast generic version
Hyderabad based Dr Reddy’s Laboratories Ltd. has recently launched osteoporosis treating
zoledronic acid injection in the US market. The drug is a generic version of Swiss
pharmaceutical company Novartis AG’s Reclast (zoledronic acid) injection which is a
treatment for women suffering from osteoporosis post menopause. The injection is being
made available in a single use vial for intravenous infusion.
USFDA approval for the generic version will make the injection available at a price less than
at what Reclast is currently available now in the US bringing relief to its patients.
Elder penetrates cosmetics segment Mumbai based Elder Pharmaceuticals has plans of penetrating the Indian cosmetics segment.
The company will be investing INR 150 mn to INR 200 mn within the next 2‐3 years for
manufacturing and marketing of their products. The launch of new product line comes after
the company’s 40%‐60% partnership with Japan's Kose Corporation, which has been named
Kose Elder (India) Pvt. Ltd. for an interim period and will be involved in manufacturing and
selling Made in India cosmetics.
The companies will be focusing on skincare and body‐care products which will be essentially
available as OTC and cater to both mass as well as prestige segments.
Ranbaxy partners with Daiichi Sankyo to expand pharmaceutical business in Latin
America Gurgaon based Ranbaxy Laboratories are looking towards expanding its business in Latin
America by collaborating with its Japanese parent Daiichi Sankyo in pharmaceutical market.
Ranbaxy will be supporting its parent company’s Brazilian subsidiary, Daiichi Sankyo Brasil
Farmaceutica Ltda to penetrate the branded pharmaceutical generics market along with
establishing business of providing innovative products.
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 6/15
Healthcare – Monthly Update
The business agreement will aid the Daiichi Sankyo Group to expand its presence in Brazil
through hybrid business model. Both Daiichi Sankyo and Ranbaxy are having considerable
pharmaceuticals business through innovative pharmaceuticals and generic products that are
being marketed by Daiichi Sankyo Brazil and Ranbaxy Farmaceutica respectively in Brazil.
Industry Expert Speak
Glivec faces patent plea dismissal – Ameet Hariani, Managing Partner - Hariani & Co.
Law Firm
“Henceforth, multinational pharma companies are likely to want that their patents are first
recognised in India before launch of a patented product.”
MSD Pharma
files
patent
infringement
litigation
against
Glenmark
– Ali
Asghar
Dholkawala, advocate and IP expert - Wadia Ghandy and Co. Law Frm
“Any data submitted to the government is not considered patent infringement under the
patent act. Also, grant of marketing approval doesn't amount to patent infringement under
the Drugs and Cosmetics Act of India.”
Pharmexcil to set up pharma storage warehouses abroad – Bhavin Mehta, Member –
Pharmexcil
"We have invited a large number of drug regulators from overseas market, which will
immensely help local pharma companies to promote the quality and affordability aspect as
envisaged in 'Brand India Pharma' campaign. The campaign has been initiated by Ministry of
Commerce and executed by Pharmexcil.
Transactions (Feb 2013 – Apr 2013)
Date Buyer Target Deal Size
(INR mn) % stake Deal Status
Type of
Transaction
25th Apr2013
InternationalFinance
Corporation
FortisHealthcare Ltd.
542 6 Planned Private Equity
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 7/15
Healthcare – Monthly Update
23rd Apr2013
Somerset
Indus Capital
Partners
Cygnus
Medicare Pvt.
Ltd.
N.A. N.A. Completed Private Equity
16th Apr2013
FulcrumVenture India
ShieldHealthcare Pvt.
Ltd.218.2 N.A. Completed Private Equity
15th Apr
2013
Seedfund
&
AsianHealthcare
Fund
Total Dental
Care Pvt. Ltd. 500 N.A. Completed Private Equity
12th Apr2013
Singaporebased investor
Amrish
OncologyServices Pvt.
Ltd.
330 N.A. Completed Private Equity
12th Apr2013
OrbiMedAdvisors
ClarisLifesciencesLtd.
2013.04 N.A. Completed Private Equity
2nd Apr2013
India VentureAdvisors
Global BarodaHospital
N.A. N.A. Completed Private Equity
1st Apr2013
MortaraInstruments
IncCardiac Science 1140 N.A. Planned M&A
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 8/15
Healthcare – Monthly Update
25th Mar2013
ChrysCapital
Ipca
Laboratories
Ltd.
2174 4 Completed Private Equity
22nd Mar2013
Jacob BallasCapital India
Pvt. Ltd.
Vivimed LabsLtd.
670 13.1 Completed Private Equity
22nd Mar
2013
Quadria
Capital
Milestone
Religare
Investment Advisors Pvt.
Ltd.
N.A. 100 Completed Private Equity
20th Mar2013
Intel andSequoiaCapital
Healthkart 760 N.A. Completed Private Equity
15th Mar2013
Fresenius KabiIndia Pvt. Ltd.
ParenteralDrugs IndiaLtd.
2000 N.A. Completed M&A
13th Mar2013
Route One Strides Arcolab 558.1 N.A. Completed Private Equity
11th Mar2013
Temasek Holdings
HealthcareGlobal
Enterprises
(HCG)
1400 N.A. Completed Private Equity
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 9/15
Healthcare – Monthly Update
2nd Mar2013
IFC Hikal Ltd. 435 N.A. Planned Private Equity
28th Feb2013
Cipla Ltd.Cipla MedproSouth Africa
Ltd.391.32 N.A. Completed M&A
28th Feb
2013 Mylan Inc.
Agila
Specialties Pvt.Ltd.
86,000 100 Completed M&A
25th Feb2013
WestBridge
CapitalPartners
&
TA Associates
Dr. LalPathLabs
2,434 N.A. Completed Private Equity
25th Feb2013
LighthouseFunds
SurakshaDiagnostic Pvt.Ltd.
500 N.A. Completed Private Equity
21st Feb2013
HelionVenturePartners
LifeCellInternational
350 N.A. Completed Private Equity
19th Feb2013
IMCD GroupB.V
IndchemInternational
N.A. N.A. Completed M&A
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 10/15
Healthcare – Monthly Update
14th Feb2013
Vivimed LabsFinoso Pharma
Pvt. Ltd.150 N.A. Completed M&A
8th Feb2013
Ma FoiStrategic
Consultants
Oviya MedSafePvt. Ltd.
N.A. 17.5 Completed M&A
Annual Financial Results – Revenue (INR mn)
Companies FY ‘09 FY ‘10 FY ‘11 FY ‘12
Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0
Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5
Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7
Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0
Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0
Dr. Reddy’s Laboratories
(DRL)69,441.00 70,277.00 74,693.00 96,737.4
GlaxosmithKline ConsumerHealthcare Ltd.
19,757.6 23,693.3 27,688.6 28,857.3
Glenmark PharmaceuticalsLtd.
21,241.20 25,291.30 29,490.70 40,206.4
Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5
Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1
Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 11/15
Healthcare – Monthly Update
Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543
Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3
Ranbaxy Laboratories Ltd. 75,970.40 89,607.70 101,614.1 117,153.2
Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9
Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1
Sun PharmaceuticalsIndustries Ltd.
42,723.00 38,086.30 57,214.30 80,056.6
Torrent Pharmaceuticals Ltd. 16,306.60 19,160.40 22,264.80 26,959.2
Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0
* Change in Financial Year Ending
Annual Financial Results – Income (INR mn)
Companies
FY
‘09
FY
‘10
FY
‘11
FY
‘12
Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0
Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0
Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9
Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4
Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0
Dr. Reddy’s Laboratories
(DRL)‐5,168.00 1,068.00 11,040.00 14,262.1
GlaxoSmithKline ConsumerHealthcare Ltd.
2,327.8 2,998.5 3,552.1 3,765.6
Glenmark Pharmaceuticals
Ltd.1,916.60 3,244.70 4,532.10 4,603.5
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 12/15
Healthcare – Monthly Update
Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6
Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5
Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7
Opto Circuits (India) Ltd. 2,087.3 2,603.0 3,672.5 5,718.8
Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0
Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5
Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6
Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4
Sun Pharmaceuticals
Industries Ltd.18,177.30 13,510.80 18,160.60 25,872.5
Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4
Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1
* Change in Financial Year Ending
Quarterly Financial Results – Revenue (INR mn)
Companies Jan-Mar
2012
Apr-Jun
2012
Jul-Sep
2012
Oct -Dec
2012
Biocon Ltd. 5,892.2 5,770.0 5,924.0 6,342.2
Blue Star Ltd. N.A. N.A. N.A. N.A.
Cadila Healthcare Ltd. 14,633.9 15,161.0 15,476.4 16,041.1
Cipla Ltd. N.A N.A. N.A. N.A.
Dabur India Ltd. 13,858.3 14,620.0 15,372.2 16,307.2
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 13/15
Healthcare – Monthly Update
Dr. Reddy’s Laboratories
(DRL)26,584.0 25,406.0 28,809.0 28,651.6
GlaxoSmithKline Consumer
Healthcare Ltd.
8,608.7 7,869.6 8,275.4 7,090.7
Glenmark PharmaceuticalsLtd.
10,751.2 10,404.1 12,551.9 13,812.6
Jubilant life Sciences Ltd. 12,235.9 12,358.9 12,197.3 13,018.1
Lupin Ltd. 20,063.7 22,191.5 22,392.6 24,658.7
Nestle India Ltd. 20,558.7 19,865.8 21,155.9 21,526.4
Opto Circuits (India) Ltd. 6,627.0 7,150.6 6,070.1 6,187.8
Piramal Enterprises Ltd. 7,055.3 7,472.4 8,630.3 9,935.7
Ranbaxy Laboratories Ltd. 36,954.0 31,740.6 26,513.9 (68,096.4)
Siemens India Ltd. 37601.432 34,141.3 34,141.3 24,508.6
Strides Arcolab Ltd. 5,274.7 5,082.9 5,773.4 N.A.
Sun PharmaceuticalsIndustries Ltd.
23,299.3 26,581.4 26,638.6 28,520.1
Torrent Pharmaceuticals Ltd. 6,686.8 7,356.0 7,471.7 7,686.3
Wockhardt Ltd. 12,413.90 14,258.2 13,474.4 14,350.4
Quarterly Financial Results – Income (INR mn)
Companies Jan-Mar
2012
Apr-Jun
2012
Jul-Sep
2012
Oct -Dec
2012
Biocon Ltd. 978.0 790.0 896.5 917.6
Blue Star Ltd. N.A. N.A. N.A. N.A.
Cadila Healthcare Ltd. 1,708.8 1,947.9 951.4 1,029.1
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 14/15
Healthcare – Monthly Update
Cipla Ltd. N.A. N.A. N.A. N.A.
Dabur India Ltd. 1,705.1 1,494.0 2,023.7 2,111.1
Dr. Reddy’s Laboratories(DRL)
3,427.0 3,360.0 3,925.0 3,633.1
GlaxoSmithKline Consumer
Healthcare Ltd.1,319.7 1,066.0 1,285.5 696.5
Glenmark PharmaceuticalsLtd.
1,482.7 782.8 1,567.5 2,129.2
Jubilant life Sciences Ltd. ‐635.3 50.1 1,520.0 266.9
Lupin Ltd. 1,556.4 2,803.9 2,904.6 3,352.3
Nestle India 2,757.3 2,459.7 2,673.1 2,789.3
Opto Circuits (India) Ltd. 2,093.5 1,380.2 1,162.4 1,132.6
Piramal Enterprises Ltd. (386.8) 40.8 (920.2) 610.7
Ranbaxy Laboratories Ltd. 12,467.6 ‐5,857.3 7,541.7 (19,076.6)
Siemens India Ltd. 3,040.0 (157.6) (157.6) 730.7
Strides Arcolab Ltd. 6,420.7 904.8 524.9 N.A.
Sun PharmaceuticalsIndustries Ltd.
8202.1 7,955.5 3,196.4 8,813.0
Torrent Pharmaceuticals Ltd. ‐16.5 1,018.5 1,072.5 1,123.3
Wockhardt Ltd. ‐1,916.4 3,779.7 4,535.5 4,278.4
7/30/2019 Healthcare Sector in India Monthly Update April 2013
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-april-2013 15/15
Healthcare – Monthly Update
Research on India (ROI) is a leading source for market research on various sectors in India
that offers premium research content from worldwide publishers of market research
reports.
Contact us:
W: www.researchonindia.com
T: India (Toll Free): 1800 102 1133; International: +91 (33) 4027 6214/5
Connect with Us
Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.
Events Calendar
Hands-on
Workshop
on
Molecular
Biotechnology and Bioinformatics Date: 6th to 10th May 2013
Venue: International Center for Stem Cells,Cancer and Biotechnology (ICSCCB), Pune
City: Pune, MaharashtraContact Person: Prof. Dr. Sheo Mohan SinghOrganizer: ICSCCB
Contact No: +91 9545089202E‐Mail: [email protected]
Website: icsccb.org/workshops
Drug Delivery
&
Complex
Generics
Date: 28th to 30th May 2013Venue: Holiday Inn International, Sakinaka
JunctionCity: Mumbai, MaharashtraContact Person: Pallavi Mhapankar
Organizer: UBM IndiaContact No: +91 22 61727001/+91 22 61727272
Website: atnd.it/11koVgA